A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
Latest Information Update: 05 Jul 2022
At a glance
- Drugs CKD-393 (Primary)
 - Indications Type 2 diabetes mellitus
 - Focus Pharmacokinetics
 - Sponsors Chong Kun Dang
 
Most Recent Events
- 27 Jun 2022 Status changed from recruiting to completed.
 - 28 Apr 2022 New trial record